Cipla USA, Inc. recalls
19 recalls filed under Cipla USA, Inc.. The most recent was published October 14, 2026.
-
Class II · 11 days ago
Cipla USA, Inc. Fosfomycin Tromethamine Granules for Oral Solution recall: Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications
-
Class II · 4 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 60 mg, 30-count bottle recall: cGMP Deviations: presence of N-nitroso-cinacalcet
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class II · 4 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle recall: cGMP Deviations: presence of N-nitroso-cinacalcet
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class II · 4 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle recall: cGMP Deviations: presence of N-nitroso-cinacalcet
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class II · 6 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle recall: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class II · 6 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle recall: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class II · 6 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle recall: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class II · 6 months ago
Cipla USA, Inc. Lanreotide Injection, 120 mg*/0.5 mL recall: Lack of Assurance of Sterility: Due to an FDA observation at the contract
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
-
Class II · 6 months ago
Cipla USA, Inc. Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe recall: Lack of Assurance of Sterility: Due to an FDA observation at the contract
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
-
Class III · 8 months ago
Cipla USA, Inc. Nilotinib Capsules, 200 mg per capsule, packaged in cartons recall: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
-
Class III · 8 months ago
Cipla USA, Inc. Nilotinib Capsules, 150 mg per capsule, packaged in cartons recall: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
-
Class III · 9 months ago
Cipla USA, Inc. Diclofenac Sodium Topical Gel, 1% recall: Failed PH Specifications
Failed PH Specifications
-
Class II · 9 months ago
Cipla USA, Inc. Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe recall: Presence of Particulate Matter
Presence of Particulate Matter.
-
Class II · 10 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle recall: CGMP Deviations: the presence of a nitrosamine impurity
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
-
Class II · 10 months ago
Cipla USA, Inc. Lanthanum Carbonate chewable tablets, 1000mg* recall: Failed stability specifications: Out of specification for hardness test
Failed stability specifications: Out of specification for hardness test
-
Class II · 10 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle recall: CGMP Deviations: the presence of a nitrosamine impurity
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
-
Class II · 10 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle recall: CGMP Deviations: the presence of a nitrosamine impurity
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
-
Class II · 10 months ago
Cipla USA, Inc. Lanthanum Carbonate chewable tablets, 1000mg* recall: Failed stability specifications: Out of specification for hardness test
Failed stability specifications: Out of specification for hardness test
-
Class II · 11 months ago
Cipla Limited Phytonadione Injectable Emulsion, USP 10mg/mL recall: Failed Stability Specifications: Observed OOS results: eg results for colour
Failed Stability Specifications: Observed OOS results: eg results for colour index
About this page
Cipla USA, Inc. appears here because a federal agency named it as the recalling firm or the brand on the label. A recall is not a judgement about everything the company sells — it covers only the lot codes and models listed in each notice.